On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGE-A

Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis

Metronomic chemotherapy with cytotoxic agents has been shown to inhibit angiogenesis and, consequently, tumor growth by targeting vascular endothelial cells (ECs). In these regimens, anti-tumor activities additional to anti-angiogenesis may operate. Moreover, chemotherapy typically generates reactive oxygen species in targeted ECs, which can affect angiogenesis. The aim of the present study was...

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

The promising but still limited efficacy of angiogenesis inhibitors as monotherapies for cancer treatment indicates a need to integrate these agents into existing therapeutic regimens. Presently, we investigate the antitumor activity of the small-molecule angiogenesis inhibitor axitinib (AG-013736) and its potential for combination with metronomic cyclophosphamide. Axitinib significantly inhibi...

Antiangiogenic metronomic chemotherapy.

Accessible online at: www.karger.com/onk Fax +49 761 4 52 07 14 E-mail [email protected] www.karger.com Most of the phase I–II clinical studies performed up to now used ‘metronomic-like’ schedules of cytostatic agents, often administered using weekly schedules of vinca alkaloids, taxanes, anthracyclines or alkylating agents resulting, however, in high dose-density treatments. A rational ide...

Metronomic chemotherapy beyond misconceptions.

a study on insurer solvency by panel data model: the case of iranian insurance market

the aim of this thesis is an approach for assessing insurer’s solvency for iranian insurance companies. we use of economic data with both time series and cross-sectional variation, thus by using the panel data model will survey the insurer solvency.